MwanzoFGEN • NASDAQ
add
FibroGen Inc
Bei iliyotangulia
$ 8.25
Bei za siku
$ 8.23 - $ 8.45
Bei za mwaka
$ 4.85 - $ 21.88
Thamani ya kampuni katika soko
34.06M USD
Wastani wa hisa zilizouzwa
elfu 31.84
Uwiano wa bei na mapato
0.16
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
The Motley Fool
saa 7 zilizopita
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
0.60%
0.19%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 1.08M | 774.80% |
Matumizi ya uendeshaji wa biashara | 5.30M | -43.44% |
Mapato halisi | 200.64M | 1,274.41% |
Kiwango cha faida halisi | elfu 18.65 | 234.25% |
Mapato kwa kila hisa | 49.61 | 13,491.78% |
EBITDA | -5.18M | 81.77% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 117.98M | -9.94% |
Jumla ya mali | 137.01M | -48.18% |
Jumla ya dhima | 119.53M | -74.36% |
Jumla ya hisa | 17.48M | — |
hisa zilizosalia | 4.05M | — |
Uwiano wa bei na thamani | -1.96 | — |
Faida inayotokana na mali | -8.52% | — |
Faida inayotokana mtaji | 52.71% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 200.64M | 1,274.41% |
Pesa kutokana na shughuli | -1.85M | 77.95% |
Pesa kutokana na uwekezaji | 87.16M | 11,444.37% |
Pesa kutokana na ufadhili | -85.92M | -67,551.18% |
Mabadiliko halisi ya pesa taslimu | -1.87M | 80.78% |
Mtiririko huru wa pesa | 72.84M | 1,077.84% |
Kuhusu
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2025, FibroGen was mainly reduced to a single early-stage oncology drug candidate. Wikipedia
Ilianzishwa
1 Jan 1993
Makao Makuu
Tovuti
Wafanyakazi
225
